Skip to Main Content

Author Details

Geoffrey Shouse
City of Hope National Medical Center
2007
38
11
PMIDPaper TitleJournal TitlePublished Year
38091577Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.Blood Adv2024
36094847Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.Blood Adv2023
37668287Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.Am J Hematol2023
37551951Update on bi-specific monoclonal antibodies for blood cancers.Curr Opin Oncol2023
37946255Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.J Hematol Oncol2023
37259597Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.Haematologica2023
37158890Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.J Hematol Oncol2023
37420267T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.Mol Cancer Ther2023
37081733Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.Cancer Med2023
37015335Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.J Natl Compr Canc Netw2023
36980632Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.Cancers (Basel)2023
37173225Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.Blood Rev2023
37226703TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.Haematologica2023
36735393A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.Blood Adv2023
36269847Postibrutinib relapse outcomes for patients with marginal zone lymphoma.Blood Adv2023
34635797Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.Bone Marrow Transplant2022
35842643Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.J Hematol Oncol2022
35855508Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.Curr Opin Oncol2022
35420395CAR T-Cell Therapy in the Older Person: Indications and Risks.Curr Oncol Rep2022
35296646Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.Cell Death Dis2022
35196377An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.Blood Adv2022
34111306Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.J Clin Pharm Ther2021
33658659Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.Leukemia2021
34474474Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.Blood Adv2021
34626362Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).Cancer Treat Res2021
34264504Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.BioDrugs2021
34168050The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.Clin Cancer Res2021
31741284Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.Curr Hematol Malig Rep2019
29599423Atypical Presentation of Gelsolin Amyloidosis in a Man of African Descent with a Novel Mutation in the Gelsolin Gene.Am J Case Rep2018
29725548A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.Case Rep Hematol2018
27531894Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Oncotarget2016
27613060Aberrant splicing and drug resistance in AML.J Hematol Oncol2016
23723076B56γ tumor-associated mutations provide new mechanisms for B56γ-PP2A tumor suppressor activity.Mol Cancer Res2013
22315229HEAT repeat 1 motif is required for B56γ-containing protein phosphatase 2A (B56γ-PP2A) holoenzyme assembly and tumor-suppressive function.J Biol Chem2012
21460856ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ-PP2A.Oncogene2011
20473327A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.Oncogene2010
17967874Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.Mol Cell Biol2008
17245430A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.EMBO J2007
  • 1 - 38 of 38

Recommended Authors

Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 6
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 3
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Career Start Year 2011
Number of shared co-authors 2
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 0
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 1
Sameer A Parikh
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 1
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 0
Milos D Miljkovic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 0
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2006
Number of shared co-authors 7
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 7
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 3
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 2
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 6
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 7
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 7
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Career Start Year 1998
Number of shared co-authors 2
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 1
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 2
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 0
Francisco Vega
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 7
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 1
Suzanne Trudel
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1990
Number of shared co-authors 0
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 3
Giorgio Inghirami
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 1984
Number of shared co-authors 0

Collaborators

Alexey V Danilov
City of Hope National Medical Center
Co-authored papers 9
Sayan Mullick Chowdhury
Co-authored papers 5
Olga V Danilova
City of Hope National Medical Center
Co-authored papers 2
Shalin Kothari
Yale University
Co-authored papers 2
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Andrea Sitlinger
Duke University School of Medicine
Co-authored papers 1
Vi Lam
City of Hope National Medical Center
Co-authored papers 1
Carly Roleder
City of Hope National Medical Center
Co-authored papers 1
Tamilla Nechiporuk
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 1
Tingting Liu
City of Hope National Medical Center
Co-authored papers 1
Elana Thieme
City of Hope National Medical Center
Co-authored papers 1
Xiaoguang Wang
City of Hope National Medical Center
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 1
Nur Bruss
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 1
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 1
Release 1.2